The firm has represented the founding shareholder of PharOS Pharmaceutical in the multi-million sale of his shareholding interest to DIORAMA Investments Sicar S.A. managed by DECA Investments AIFM, an Alternative Investments Fund Manager (“AIFM”) regulated by the Hellenic Capital Markets Committee. PharOS is a pharmaceutical company developing, manufacturing and supplying generics and value added products with a presence in 98 countries, a global portfolio of more than 73 products and over 7,800 marketing authorisations worldwide.